Fresh2 Group Ltd (FRES)

$0.31

-0.02

(-4.63%)

Market is closed - opens 7 PM, 21 Jun 2024

Insights on Fresh2 Group Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.39M → 437.0K (in $), with an average decrease of 93.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.91M → -31.90M (in $), with an average decrease of 45.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.6% return, outperforming this stock by 168.2%

Performance

  • $0.30
    $0.33
    $0.31
    downward going graph

    1.94%

    Downside

    Day's Volatility :8.65%

    Upside

    6.85%

    downward going graph
  • $0.30
    $4.45
    $0.31
    downward going graph

    3.26%

    Downside

    52 Weeks Volatility :93.26%

    Upside

    93.03%

    downward going graph

Returns

PeriodFresh2 Group LtdIndex (Russel 2000)
3 Months
-63.25%
0.0%
6 Months
-63.42%
0.0%
1 Year
-92.6%
0.0%
3 Years
-94.0%
-22.6%

Highlights

Market Capitalization
8.0M
Book Value
$10.3
Earnings Per Share (EPS)
-7.4
Profit Margin
0.0%
Operating Margin TTM
-698.85%
Return On Assets TTM
-61.97%
Return On Equity TTM
-216.23%
Revenue TTM
17.0M
Revenue Per Share TTM
3.83
Quarterly Revenue Growth YOY
-69.89999999999999%
Gross Profit TTM
0.0
EBITDA
-115.6M
Diluted Eps TTM
-7.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Fresh2 Group Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Technicals Summary

Sell

Neutral

Buy

Fresh2 Group Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fresh2 Group Ltd
Fresh2 Group Ltd
-32.41%
-63.42%
-92.6%
-94.0%
-94.0%
Moderna, Inc.
Moderna, Inc.
-6.47%
47.43%
11.01%
-35.46%
814.29%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.07%
24.05%
34.11%
95.48%
226.11%
Novo Nordisk A/s
Novo Nordisk A/s
4.31%
36.25%
75.64%
241.17%
454.64%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.65%
17.66%
37.32%
151.13%
156.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fresh2 Group Ltd
Fresh2 Group Ltd
NA
NA
NA
0.0
-2.16
-0.62
NA
10.3
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fresh2 Group Ltd
Fresh2 Group Ltd
Buy
$8.0M
-94.0%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
814.29%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
226.11%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
454.64%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
156.23%
30.3
39.46%

Company Information

Organization
Fresh2 Group Ltd
Employees
75
CEO
Mr. Haohan Xu
Industry
Miscellaneous

FAQs